Assess whether biosimilarity is analytically justified (8966f8)

Situation

505(b)(2) development lead in a labeling team facing a boxed-warning debate has one working extract — biosimilar analytical similarity report — after a CMO 483 that maps to the NDA CMC module. 505(b)(2) development lead in a labeling team facing a boxed-warning debate has biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module. If that extract cannot support biosimilarity is analytically justified, the honest Pharma & Life Sciences CMC and Development Pathways output is hold.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• A CMO 483 that maps to the NDA CMC module is noise around an already-controlled CMC and Development Pathways process in a labeling team facing a boxed-warning debate, given biosimilar analytical similarity report.
• A CMO 483 that maps to the NDA CMC module is the event in biosimilar analytical similarity report that forces Proceed under protocol for 505(b)(2) development lead under Pharma & Life Sciences.
• Biosimilar analytical similarity report shows a one-file miss after a CMO 483 that maps to the NDA CMC module, not a CMC and Development Pathways program failure.
• Biosimilar analytical similarity report cannot decide biosimilarity is analytically justified yet after a CMO 483 that maps to the NDA CMC module; hold is the only Pharma & Life Sciences close a labeling team facing a boxed-warning debate can defend.

Analysis required

• Map FDA-response timing and owner in a labeling team facing a boxed-warning debate.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move biosimilarity is analytically justified for 505(b)(2) development lead.

Recommendation